# Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

> **NCT03240861** · PHASE1 · TERMINATED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 5 (actual)

## Conditions studied

- HLA-A*0201 Positive Cells Present
- Locally Advanced Malignant Neoplasm
- NY-ESO-1 Positive
- Unresectable Malignant Neoplasm
- Sarcoma

## Interventions

- **OTHER:** 18F-FHBG
- **BIOLOGICAL:** Aldesleukin
- **DRUG:** Busulfan
- **BIOLOGICAL:** Cellular Therapy
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Filgrastim
- **DRUG:** Fludarabine
- **PROCEDURE:** Leukapheresis
- **DRUG:** Plerixafor
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT03240861
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-26
- **Primary completion:** 2023-10-19
- **Final completion:** 2023-10-19
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2023-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03240861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03240861, "Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03240861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*